Epicrispr Biotechnologies
Develops programmable epigenetic medicines to treat genetic diseases like FSHD
$90MSeries C
Role not disclosedLoading investors…
Activity from announced rounds
Develops programmable epigenetic medicines to treat genetic diseases like FSHD
Developing transformative, best-in-class neuropsychiatric therapies
Pitching Janus Henderson Investors? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room